How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,767 results for

Growth Delay Onset Determination

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Growth Delay Onset Determination

Growth Delay Onset Determination Growth Delay Onset Determination Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Growth Delay Onset (...) Determination Growth Delay Onset Determination Aka: Growth Delay Onset Determination From Related Chapters II. Causes: Intrauterine Growth Retardation tic or chromosomal abnormality Transplacental infectious disease ( ) Toxins Nicotine Medications III. Causes: Birth Prolonged Panhypopituitarism IV. Causes: Childhood See Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Growth Delay Onset Determination." Click on the image (or right click

2018 FP Notebook

2. COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)

COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS) COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03223519 Recruitment Status : Completed First Posted : July 21, 2017 Last Update Posted : January 23, 2018 Sponsor

2017 Clinical Trials

3. Growth Delay Onset Determination

Growth Delay Onset Determination Growth Delay Onset Determination Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Growth Delay Onset (...) Determination Growth Delay Onset Determination Aka: Growth Delay Onset Determination From Related Chapters II. Causes: Intrauterine Growth Retardation tic or chromosomal abnormality Transplacental infectious disease ( ) Toxins Nicotine Medications III. Causes: Birth Prolonged Panhypopituitarism IV. Causes: Childhood See Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Growth Delay Onset Determination." Click on the image (or right click

2015 FP Notebook

4. Management of Neonates Born at ?34 6/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis

, and two-thirds of preterm births are associated with preterm labor, PROM, or clinical concern for intrauterine infection, risk stratification strategies cannot be applied to preterm infants in the same manner as for term neonates. In particular, the Neonatal Early-Onset Sepsis Risk Calculator does not apply to infants born before 34 0/7 weeks’ gestation. The objective of EOS risk assessment among preterm infants is, therefore, to determine which infants are at the lowest risk for infection and who (...) . , The use of 2 separate bottles may provide the opportunity to determine if commensal species are true infections by comparing growth in the two. , Use of 1 aerobic and 1 anaerobic culture bottle may optimize organism recovery. Most neonatal pathogens, including GBS, E coli , coagulase-negative Staphylococcus , and Staphylococcus aureus , will grow in anaerobic conditions. One study revealed that with routine use of both pediatric aerobic and adult anaerobic blood cultures, strict anaerobic species

2018 American Academy of Pediatrics

5. Delayed Umbilical Cord Clamping After Birth

with the neonatal care provider is essential. The ability to provide delayed umbilical cord clamping may vary among institutions and settings; decisions in those circumstances are best made by the team caring for the mother–infant dyad. There are several situations in which data are limited and decisions regarding timing of umbilical cord clamping should be individualized (Table 1). For example, in cases of fetal growth restriction with abnormal umbilical artery Doppler studies or other situations in which (...) outcomes, delayed umbilical cord clamping does not increase the risk of postpartum hemorrhage or the need for blood transfusion. Additionally, postpartum maternal hemoglobin levels are not affected by delayed compared with immediate umbilical cord clamping. References Yao AC, Moinian M, Lind J. Distribution of blood between infant and placenta after birth. Lancet 1969;2:871–3. [ ] Linderkamp O. Placental transfusion: determinants and effects. Clin Perinatol 1982;9:559–92. [ ] Philip AG, Saigal S. When

2017 American College of Obstetricians and Gynecologists

6. Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. (PubMed)

Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. Akt is a serine/threonine kinase that mediates signaling downstream of tyrosine kinase receptors like the type I insulin-like growth factor receptor (IGF-IR). In fact, we have previously shown that mammary tumors induced by elevated expression of the IGF-IR are associated with hyperactivation of Akt. However, there are three mammalian isoforms of Akt (Akt1, Akt2 and Akt3 (...) ) and these isoforms regulate distinct physiologic properties within cells. In this manuscript, the impact of disrupting Akt1 or Akt2 in mammary tumors induced by IGF-IR overexpression were examined to determine whether specific Akt isoforms regulate different aspects of mammary tumorigenesis.Akt1 and Akt2 levels were stably ablated in mammary tumors of MTB-IGFIR transgenic mice by crossing MTB-IGFIR transgenic mice with either Akt1(-/-) or Akt2(-/-) mice. Tumor onset, growth rate, and metastasis were

Full Text available with Trip Pro

2013 BMC Cancer

7. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow The present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.This was a prospective, randomized, open-label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal (...) occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatment and 24-hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoints were the decrease of National Institutes of Health Stroke Scale scores over 24 hours and the favorable shift of modified Rankin Scale score (mRS) distribution at day 90. Exploratory outcomes included vessel recanalization

Full Text available with Trip Pro

2018 EvidenceUpdates

8. Hypothalamic - Pituitary and Growth Disorders in Survivors of Childhood Cancer

hypothalamic–pituitary axis radiation. (1∣⊕⊕OO) 2.5 We suggest against using spontaneous growth hormone secretion ( e.g. , 12-hour overnight sampling) as a diagnostic test in determining GH deficiency in childhood cancer survivors. (2∣⊕OOO) 2.6 We recommend that formal testing to establish a diagnosis of growth hormone deficiency is not required in childhood cancer survivors with three other confirmed anterior pituitary hormone deficits. (1∣⊕⊕OO) 2.7 We recommend retesting adult cancer survivors exposed (...) for impaired growth and short stature in cancer survivors are CRT, CSI, TBI, and younger age at the time of treatment ( ). Exposure to 18 to 30 Gy CRT may result in GHD and precocious puberty, whereas doses >30 Gy may result in multiple pituitary hormone deficiencies ( , ). Exposure to CRT can also result in an earlier onset or altered tempo of puberty, including onset of breast development between ages 8 and 9 years, peak height velocity at age ≤10 years, and early menarche ( ). Importantly, children who

Full Text available with Trip Pro

2018 The Endocrine Society

9. Cost-Conscious Growth-Promoting Treatment: When Discretion Is the Better Part of Value

degree of disordered growth can in- terfere with day-to-day living to a degree that its treat- ment lies appropriately within the realm of medicine. The likely prospect for an adult height clearly below the statistical population normal range (e.g., < 1st percentile) might be a height threshold for diminished opportunity justifying consideration of hGH treatment on which most could agree. Beyond that, however, determining whether there is value (i.e., improved psychosocial out- come) in hGH treatment (...) of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005 Sep; 90(9): 5247–53. 26 Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri A, Monfared MF, et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone ef- fects upon growth and puberty of children with constitutional delay of puberty and idio- pathic short stature. Horm Res Paediatr. 2010; 74(6): 428–35. 27 Schroor EJ, van Weissenbruch MM, Knibbe P, Delemarre-van de

2018 Pediatric Endocrine Society

10. Asfotase alfa for treating paediatric-onset hypophosphatasia

50–100% of babies die within the first year of life, primarily because of respiratory failure. Juvenile-onset hypophosphatasia that develops later in childhood is associated with a substantially lower mortality rate than the form that appears in infancy, but is often debilitating and leads to bone deformities that may result in delayed walking, limb weaknesses, skeletal pain and non-traumatic fractures. 2.3 The prevalence of severe forms of hypophosphatasia is unknown in England. However (...) medical records of children up to 5 years. ALX-HPP-502, a retrospective natural history study of children with juvenile-onset hypophosphatasia (5–15 years). The study focused on functional assessments of physical abilities, changes in growth (height and weight) and skeletal improvement (severity of rickets). ALX-HPP-502s, a single-centre substudy of ALX-HPP-502. Data for additional functional measures were taken from medical records and videos were obtained from a longitudinal natural history database

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

11. Persistent Target Mismatch Profile &gt;24 Hours After Stroke Onset in DEFUSE 3. (PubMed)

at presentation, may experience delayed infarct expansion, and have poor clinical outcomes. Clinical trials are needed to determine if patients with a favorable perfusion profile benefit from reperfusion beyond 24 hours. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02586415. (...) Persistent Target Mismatch Profile >24 Hours After Stroke Onset in DEFUSE 3. Background and Purpose- Efficacy of endovascular thrombectomy has been demonstrated up to 24 hours after stroke onset in patients selected with perfusion imaging. We hypothesized that a persistent favorable perfusion profile exists in some patients beyond 24 hours from the onset and can be predicted by a lower baseline hypoperfusion intensity ratio, which indicates favorable collaterals. Methods- We identified

Full Text available with Trip Pro

2019 Stroke

12. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep Wake Rhythm Disorder (N24SWD), and Irregular Sleep-W

Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep Wake Rhythm Disorder (N24SWD), and Irregular Sleep-W JCSM - Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD (...) -Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015 R. Robert Auger, MD 1 ; Helen J. Burgess, PhD 2 ; Jonathan S. Emens, MD 3 ; Ludmila V. Deriy, PhD 4 ; Sherene M. Thomas, PhD 4 ; Katherine M. Sharkey, MD, PhD 5 1 Mayo Center for Sleep Medicine, Rochester, MN; 2 Rush University Medical Center, Chicago, IL; 3 Portland VA Medical Center, Portland, OR; 4 American

2015 American Academy of Sleep Medicine

13. Developing a Management Approach for Patients With "Late-Onset" Pompe Disease

features may go unrecognized in childhood without vigilant clinical examination and assessments with appropriate functional tests. In our clinical experience, children with the "late-onset" GAA variant may present much earlier in life and adult patients with LOPD consistently report a much earlier symptom onset and a significant diagnostic delay. These patients have shown improvement after initiation of ERT but have motor impairments adversely affecting their quality of life and growth from early (...) and 12 month visit. The study has three goals: To study and record disease specific clinical symptoms in newborns and infants with Pompe disease without cardiomyopathy (disease of the heart muscle) identified through newborn screening (NBS) To devise an approach to characterize early musculoskeletal (muscles and joints) involvement in subjects with the "late-onset" GAA variant identified by NBS To determine criteria to start preventative therapies including enzyme replacement therapy (ERT

2018 Clinical Trials

14. Early onset complete ovarian failure and lack of puberty in a woman with mutated estrogen receptor beta (ESR2). (PubMed)

Early onset complete ovarian failure and lack of puberty in a woman with mutated estrogen receptor beta (ESR2). Estrogen resistance due to mutations in the estrogen receptor α gene (ESR1) has been described in men and women and is characterized by osteoporosis, delayed bone age and continuous growth in adulthood, and delayed puberty and multiple ovarian cysts in women. Although mutations in the estrogen receptor β gene ESR2 were found in 46, XY patients with differences of sex development (...) in a young woman with complete ovarian failure, suggesting that ESR2 is necessary for human ovarian determination and/or maintenance and that ESR1 is not sufficient to sustain ovarian function in humans.

2018 Journal of Clinical Endocrinology and Metabolism

15. Constitutional Growth Delay (Diagnosis)

growth delay begins to drift further from the growth curve because of delay in the onset of the pubertal growth spurt. Catch-up growth, onset of puberty, and pubertal growth spurt occur later than average, resulting in normal adult stature and sexual development. However, a report by Rohani et al on males with constitutional growth delay—mean age 15.2 years at presentation and 20 years at study’s end—found that the majority of patients attained neither their target height nor their predicted adult (...) of psychosocial problems; nonreferred children with short stature do not differ from those with more normal stature in school performance or socialization. Next: Pathophysiology Constitutional growth delay is a global delay in development that affects every organ system. Delays in growth and sexual development are quantified by skeletal age, which is determined from bone age radiographic studies of the left hand and wrist. Growth and development are appropriate for an individual's biologic age (skeletal age

2014 eMedicine Pediatrics

16. Constitutional Growth Delay (Overview)

growth delay begins to drift further from the growth curve because of delay in the onset of the pubertal growth spurt. Catch-up growth, onset of puberty, and pubertal growth spurt occur later than average, resulting in normal adult stature and sexual development. However, a report by Rohani et al on males with constitutional growth delay—mean age 15.2 years at presentation and 20 years at study’s end—found that the majority of patients attained neither their target height nor their predicted adult (...) of psychosocial problems; nonreferred children with short stature do not differ from those with more normal stature in school performance or socialization. Next: Pathophysiology Constitutional growth delay is a global delay in development that affects every organ system. Delays in growth and sexual development are quantified by skeletal age, which is determined from bone age radiographic studies of the left hand and wrist. Growth and development are appropriate for an individual's biologic age (skeletal age

2014 eMedicine Pediatrics

17. Growth Disturbances ? Risk of Intrauterine Growth Restriction

of the biophysical profile (BPP), Doppler US, fetal heart rate monitoring, especially the nonstress test (NST), and fetal movement counting [10] can all contribute to the determination of fetal compensation or compromise. Assessment of fetal well-being is essential to the management of pregnancies with FGR. Assessment of fetal growth is best performed at a time interval of no less than once every 2 weeks and is likely to be more reliable at a frequency of every 3 to 4 weeks given the error inherent (...) of the utility of the fetal cerebroplacental ratio measured at term for the prediction of adverse perinatal outcome. Placenta 2017;54:68-75. 18. Cosmi E, Ambrosini G, D'Antona D, Saccardi C, Mari G. Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. Obstet Gynecol 2005;106:1240-5. 19. Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007;109:253-61. 20. Hassan WA, Brockelsby J, Alberry M, Fanelli

2012 American College of Radiology

18. Social Determinants of Risk and Outcomes for Cardiovascular Disease

Social Determinants of Risk and Outcomes for Cardiovascular Disease Social Determinants of Risk and Outcomes for Cardiovascular Disease | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Share on Jump to Free Access article Social Determinants of Risk and Outcomes for Cardiovascular Disease A Scientific Statement From the American Heart Association , MD, FAHA , PhD, MS , MD, PhD , PhD , MD, FAHA , MD, FAHA , MA(Oxon), MD, BChir(Cantab), MSc(Lond) , RN, PhD, FAHA , MD, FAHA , , and PhD MD, FAHAon behalf of the American Heart Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and Prevention, Council on Cardiovascular

2015 American Heart Association

19. TBCE Mutations Cause Early-Onset Progressive Encephalopathy with Distal Spinal Muscular Atrophy. (PubMed)

subjects from four unrelated families originated from the same geographical area in Southern Italy. Western blot analysis of patient fibroblasts documented a reduced amount of TBCE, suggestive of rapid degradation of the mutant protein, similarly to what was observed in pmn/pmn fibroblasts. The impact of TBCE mutations on microtubule polymerization was determined using biochemical fractionation and analyzing the nucleation and growth of microtubules at the centrosome and extracentrosomal sites after (...) TBCE Mutations Cause Early-Onset Progressive Encephalopathy with Distal Spinal Muscular Atrophy. Tubulinopathies constitute a family of neurodevelopmental/neurodegenerative disorders caused by mutations in several genes encoding tubulin isoforms. Loss-of-function mutations in TBCE, encoding one of the five tubulin-specific chaperones involved in tubulin folding and polymerization, cause two rare neurodevelopmental syndromes, hypoparathyroidism-retardation-dysmorphism and Kenny-Caffey syndrome

Full Text available with Trip Pro

2016 American Journal of Human Genetics

20. Transcription and chromatin determinants of de novo DNA methylation timing in oocytes (PubMed)

Transcription and chromatin determinants of de novo DNA methylation timing in oocytes Gametogenesis in mammals entails profound re-patterning of the epigenome. In the female germline, DNA methylation is acquired late in oogenesis from an essentially unmethylated baseline and is established largely as a consequence of transcription events. Molecular and functional studies have shown that imprinted genes become methylated at different times during oocyte growth; however, little is known about (...) the kinetics of methylation gain genome wide and the reasons for asynchrony in methylation at imprinted loci.Given the predominant role of transcription, we sought to investigate whether transcription timing is rate limiting for de novo methylation and determines the asynchrony of methylation events. Therefore, we generated genome-wide methylation and transcriptome maps of size-selected, growing oocytes to capture the onset and progression of methylation. We find that most sequence elements, including most

Full Text available with Trip Pro

2017 Epigenetics & chromatin

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>